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Targeting of RNA polymerase I is
currently being explored for cancer
therapeutics. Wei et al. show that small-
molecule BMH-21 activates a conserved
RNA polymerase I checkpoint that
monitors efficiency of transcription.
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Inhibition of RNA polymerase I (Pol I) is a promising
strategy for modern cancer therapy. BMH-21 is a
first-in-class small molecule that inhibits Pol I tran-
scription and induces degradation of the enzyme,
but how this exceptional response is enforced is
not known. Here, we define key elements requisite
for the response. We show that Pol I preinitiation fac-
tors and polymerase subunits (e.g., RPA135) are
required for BMH-21-mediated degradation of
RPA194. We further find that Pol I inhibition and
induced degradation by BMH-21 are conserved in
yeast. Genetic analyses demonstrate that mutations
that induce transcription elongation defects in Pol I
result in hypersensitivity to BMH-21. Using a fully re-
constituted Pol I transcription assay, we show that
BMH-21 directly impairs transcription elongation by
Pol I, resulting in long-lived polymerase pausing.
These studies define a conserved regulatory check-
point that monitors Pol I transcription and is acti-
vated by therapeutic intervention.INTRODUCTION
RNA polymerase I (Pol I) is a highly active enzyme compartmen-
talized in the nucleolus, where it synthesizes the most abundant
RNA species in the cell, the rRNAs (McStay and Grummt, 2008).
Transcription of rDNA by Pol I is the first, rate-limiting step in
ribosome biogenesis (Haag and Pikaard 2007; Russell and Zo-
merdijk 2006). The rate of ribosome biosynthesis is proportional
to cell growth and proliferation (Grummt 2010; Warner et al.,
2001). The relationship between ribosome synthesis and aggres-
sive cancer cell growth has been appreciated for more than a
century and was initially described by observation of enlarged
nucleoli in tumor cells (Montanaro et al., 2008). More recently,
factors driving Pol I transcription in cancers have been identified.
These include oncogenic activity by Myc, Ras/ERK, mTOR, and
Akt/PKB and loss of Pol I repression by tumor suppressors p53,
Rb, ARF, and PTEN genomic alterations (Bywater et al., 2013;404 Cell Reports 23, 404–414, April 10, 2018 ª 2018 The Authors.
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deregulation of Pol I transcription in human cancers, Pol I has
been an underexplored target for selective inhibition of cancer
cell growth. Recent identification of several small-molecule in-
hibitors of Pol I (BMH-21, BMH-9, BMH-22, BMH-23, CX-5461,
and ellipticine) have provided new tools to assess the links be-
tween Pol I transcription and cancer growth (Andrews et al.,
2013; Bywater et al., 2012; Drygin et al., 2011; Morgado-Palacin
et al., 2014; Peltonen et al., 2014a, 2014b). Studies in vitro and in
mouse models have shown therapeutic efficacy by the rRNA
transcription inhibitors (Bywater et al., 2012; Drygin et al.,
2011; Peltonen et al., 2014a). Translation of these advances to
cancer care will require identification of the mechanisms by
which the inhibitors influence Pol I.
We discovered the small-molecule BMH-21 in a high-
throughput screen for anticancer agents (Peltonen et al., 2010).
BMH-21 blocks Pol I transcription rapidly and profoundly and in-
duces proteasome-mediated degradation of the largest subunit
of Pol I, RPA194 (Peltonen et al., 2014a). This effect is unique to
BMH-21 and is not observed by other inhibitors that affect Pol I
(CX-5461, actinomycin D, topoisomerase I, and II poisons) (Pel-
tonen et al., 2014a). BMH-21 binds GC-rich DNA in a non-cova-
lent, charge-dependent manner without activating a DNA dam-
age response (Colis et al., 2014a; Peltonen et al., 2010, 2014a).
We have shown that BMH-21 causes destabilization of
RPA194 in a manner independent of several DNA damage and
replication checkpoint kinases (Colis et al., 2014a; Peltonen
et al., 2014a). Furthermore, the degradation of RPA194 corre-
lates with BMH-21-mediated cancer cell death. These findings
indicate that degradation of RPA194 may reflect a regulatory
step in Pol I transcription and be of therapeutic value.
The large subunit of Pol II, Rpb1, is degraded in response to
stalled transcription complexes, and this pathway is considered
a regulatory process by which cells resolve transcription elonga-
tion blocks (Wilson et al., 2013). BMH-21 does not affect Rpb1
under conditions in which RPA194 is degraded, but on the other
hand, cell stresses that cause Rpb1 degradation do not affect
RPA194 (Peltonen et al., 2014a). Thus, the pathways thatmonitor
transcription and induce degradation of Pols I and II are distinct.
Pols I and II are structurally and functionally related multisubu-
nit polymerases (Engel et al., 2013; Ferna´ndez-Tornero et al.,
2013; Martinez-Rucobo and Cramer 2013). We recentlycreativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Rapid Inhibition of Pol I Transcrip-
tion and Dissociation of Pol I from rDNA
(A) A375 and HCT116 cells treated with increasing
doses of BMH-21 for 72 hr were analyzed by cell
counting, WST1, and CellTiter Blue viability as-
says. Expression of nucleolar RPA194 was
analyzed using immunofluorescence and quanti-
tative analysis.
(B) Diagram of human rRNA coding locus and
location of qPCR and ChIP primers.
(C) A375 cells were treated with BMH-21 (1 mM) for
the indicated times, and rRNA synthesis was
analyzed by qRT-PCR using primers for short-lived
50ETS (50-external transcribed spacer) rRNA.
50ETS primer locations as shown in (B). Mean ±
SEM of n = 5 biological replicates are shown.
(D) A375 cells were treated with BMH-21 (1 mM) for
the indicated times followed by western blotting
analysis for RPA194 and RPA135.
(E) RPA194 ChIP-qPCR of A375 cells treated with
BMH-21 (1 mM) for the indicated times. Primer lo-
cations are shown in (B). Data are represented as
mean ± SEM of n = 3 biological replicates.
See also Figure S1.published that Pols I and II have evolved divergent enzymatic
properties, resulting in potentially different rate-limiting steps
during transcription elongation (Schneider 2012; Viktorovskaya
et al., 2013). These findings led us to test the hypothesis that
BMH-21 impairs transcription elongation by Pol I. We find that
BMH-21 leads to rapid clearance of Pol I from rDNA and that
this effect depends on efficient transcription initiation. We
show that RPA194 is stabilized by association with RPA135,
the second largest catalytic subunit, and depletion of RPA135
prevents degradation of RPA194 in the presence of BMH-21.
Remarkably, the effects of BMH-21 on Pol I are conserved in
Saccharomyces cerevisiae (brewer’s yeast). BMH-21 treatment
results in decreased Pol I transcription, degradation of A190
(the RPA194 homolog), and reduced cell viability. Furthermore,
yeast strains in which Pol I transcription elongation is selectivelyCimpaired are hypersensitive to BMH-21,
supporting the idea that BMH-21, at least
in part, directly affects Pol I transcription.
Finally, we use fully reconstituted tran-
scription assays in vitro to demonstrate
that BMH-21 directly inhibits Pol I tran-
scription elongation, inducing pausing.
These findings reveal a new, conserved
Pol I-specific transcription checkpoint.
RESULTS
Rapid Inhibition of Pol I and
Clearance of the Enzyme from rDNA
We have shown that inhibition of Pol I
by BMH-21 activates a unique cellular
response resulting in the degradation of
RPA194 and that this degradation corre-
lates with its effectiveness to decreasecancer cell viability (Peltonen et al., 2014a). To define the cellular
response to BMH-21 in more detail, we treated two cancer cell
lines with increasing concentrations of BMH-21 and tested for
loss of cell viability using three different readouts for cellular ac-
tivity (mitochondrial membrane potential, protein content, and
cell number) and compared those data with the nucleolar abun-
dance of RPA194. We found that loss of RPA194 tightly corre-
lated with decreased cell fitness in all assays after treatment
with BMH-21 (Figure 1A).
To describe the kinetics of the response to BMH-21, we
treated A375 cells with 1 mM BMH-21 and measured rRNA syn-
thesis and Pol I occupancy of the rDNA. The 50-external tran-
scribed spacer (50ETS) precursor is cleaved from the primary
rRNA transcript by early and rapid processing steps (01 and
A1) (Figure 1B), resulting in a short-lived RNA species whoseell Reports 23, 404–414, April 10, 2018 405
abundance is generally reflective of the rRNA synthesis rate
(Mullineux and Lafontaine 2012; Popov et al., 2013). We
measured 50ETS precursor abundance using several primer
pairs by qPCR in cells treated with BMH-21 for 5, 15, 30, and
60 min (Figures 1B and 1C). We observed rapid (within 5 min)
decrease of the 50ETS transcripts that was especially prominent
using primers for the short-lived 50 end of the ETS transcript (up-
stream of the 01 cleavage site). The decrease of the 50ETS tran-
scripts downstream of the 01 cleavage site was slower, consis-
tent with their longer half-lives (Figure 1C). Regardless of the
50ETS primer used, a prominent inhibition of transcription was
observed within 1 hr.
We then assessed Pol I occupancy of the rDNA after BMH-21
treatment using chromatin immunoprecipitation (ChIP). Given
that we have previously shown that BMH-21 decreases the
half-life of RPA194 from more than 20 hr to approximately 1 hr
(Peltonen et al., 2014a), we first determined the abundance of
RPA194 by western blotting over a time course relevant for this
study. BMH-21 caused a prominent decrease of RPA194 within
3 hr (Figure 1D). In addition, we observe some decrease in
RPA135, in accordance with our previous findings (Peltonen
et al., 2014a). We then performed ChIP qPCR of cells treated
with BMH-21 for 0.5, 1, 3, or 6 hr using primers throughout the
gene body. The data showed that RPA194 was disengaged
from both the promoter and coding regions of the rDNA within
30 min of treatment (Figure 1E). Thus, the kinetics of loss of
RPA194 chromatin engagement was faster than the protein’s
degradation.
We have shown that the turnover of RPA194 is dependent on
the proteasome (Peltonen et al., 2014a). To further assess
whether the loss of Pol I chromatin engagement results from
its turnover, we treated cells with BMH-21 andMG132, a protea-
some inhibitor. As assessed by immunofluorescence and west-
ern blotting, and consistent with our previous observations,
MG132 abolished the decrease in RPA194 by BMH-21 and
led to substantial accumulation of RPA194 and the second
largest subunit, RPA135, in the nucleolar caps (Figures S1A
and S1B).
We then conducted ChIP-qPCR of cells treated with BMH-21
and MG132. Treatment of cells with MG132 somewhat
increased RPA194 on the gene body (Figure S1C). Enrichment
of RPA194 on the gene body following co-treatment of cells
with BMH-21 andMG132 was similar to the control (Figure S1C).
This finding suggests that BMH-21 causes loss of RPA194 from
rDNA in a manner that is at least partially dependent of RPA194
turnover.
Depletion of the Preinitiation Complex Factors Rescues
RPA194 Degradation
We hypothesized that BMH-21 impairs transcribing Pol I com-
plexes. If engaged Pol I transcription complexes are targets of
BMH-21-mediated protein turnover, then efficient transcription
initiation would be required to observe degradation of RPA194.
To test this hypothesis, we silenced factors required for tran-
scription initiation by Pol I: UBF, RRN3, and TAFI110. For each
depletion, two independent small interfering RNAs (siRNAs)
were used against each gene, and the depletion was confirmed
by western blotting (Figure 2) and qPCR (not shown). We then406 Cell Reports 23, 404–414, April 10, 2018treated the cells with BMH-21 and assessed changes in abun-
dance of RPA194 by western blotting and immunofluorescence.
As shown in Figure 2, depletion of each transcription initiation
factor led to rescue of RPA194 abundance in the BMH-21-
treated cells. Yet BMH-21 decreased Pol I transcription in the
knockdown cells, as shown by 50ETS qPCR and markers of
nucleolar stress in UBF-depleted cells, showing that transcrip-
tion inhibition alone was insufficient to cause RPA194 loss (Fig-
ure S2). The findings suggested that degradation of RPA194 re-
quires efficient loading of Pol I onto the rDNA.
BMH-21 Causes Cytoplasmic Redistribution of RPA135
The two largest Pol I subunits, RPA135 and RPA194, associate
and form the active center of Pol I (Engel et al., 2013; Ferna´n-
dez-Tornero et al., 2013; Schneider and Nomura, 2004). We
have shown that although RPA194 is dramatically depleted after
treatment with BMH-21, RPA135 abundance is only mildly
affected (Peltonen et al., 2014a). To identify the fate of RPA135
after treatment, we analyzed the effect of BMH-21 on RPA135
cellular distribution. Using immunofluorescence followed by
quantitative analysis, we observed that RPA135 nucleolar local-
ization was decreased over time (Figures 3A and 3B). The ki-
netics of loss of RPA135 from the nucleolus was similar to that
of RPA194 (Figures 3C and 3D) (Peltonen et al., 2014a). Fraction-
ation of cellular extracts showed that BMH-21 caused obvious
relocation of RPA135 into the cytoplasm, whereas RPA194
abundance decreased in both cytoplasm and nucleoplasm (Fig-
ures 3E and 3F). These changes were evident already within
30 min of exposure to BMH-21 and coincided with the observed
decrease in Pol I occupancy of the rDNA after treatment
(Figure 1E).
We show in Figure 2A that RPA194 and RPA135 were retained
in the nucleolar caps following treatment with BMH-21 and
MG132. To assess the distribution of the Pol I proteins biochem-
ically, we conducted cellular fractionation of cells treated in the
presence or absence of BMH-21 and MG132 for 3 hr. The cyto-
plasmic translocation of RPA135 was again evident following
exposure to BMH-21, but this effect was abrogated by MG132
(Figure 3G). Together, these data show that BMH-21 treatment
results in degradation of RPA194, but redistribution of RPA135,
suggesting that RPA135 nucleolar localization depends on
RPA194.
RPA135 Is Requisite for the Stability of RPA194
On the basis of the above findings, it is reasonable to expect that
dissociation of RPA194 from RPA135 may reduce RPA194 sta-
bility while at the same time affecting RPA135 distribution. To
test this model, we examined the effects of RPA135 depletion
on RPA194 abundance. RPA135 transcript and protein were
effectively decreased by siRNA treatment (Figures 4A–4D). Strik-
ingly, the depletion of RPA135 also led to a pronounced
decrease in RPA194, as shown by immunofluorescence analysis
and western blotting (Figures 4B–4D). Furthermore, we did not
observe any further decrease in RPA194 by BMH-21 in the
RPA135-depleted cells (Figures 4C and 4D), consistent with
the model that only transcriptionally active Pol I complexes are
subject to BMH-21-induced degradation. These data show
that RPA194 is unstable in the absence of RPA135.
Figure 2. Depletion of the Preinitiation Factors Rescues RPA194 Degradation by BMH-21
(A and B) A375 cells were transfectedwith two siRNAs targeting UBF, incubated for 72 hr, and treatedwith BMH-21 for 3 hr. (A)Western blotting for UBF, RPA194,
and NCL as loading control. Representative blots of n = 2 experiments. (B) Immunofluorescence analysis for RPA194. Merged images (RPA194, red; DNA, blue)
are shown. Scale bar, 10 mm.
(C andD) Depletion of RRN3 using siRNAs. A375 cells were transfected with two siRNAs targeting RRN3, incubated for 72 hr, and treatedwith BMH-21 for 3 hr. (C)
Western blotting for RRN3, RPA194, and a-tubulin as loading control. Representative blots of n = 2 experiments. (D) Immunofluorescence analysis for RPA194.
Merged images (RPA194, green; DNA, blue) are shown. Scale bar, 10 mm.
(E and F) Depletion of TAF1C using siRNAs. A375 cells were transfected with two siRNAs targeting TAF1C, incubated for 72 hr, and treated with BMH-21 for 3 hr.
(E)Western blotting for TAF1C, RPA194, and GAPDH as loading control. Representative blots of n = 4 experiments. (F) Immunofluorescence analysis for RPA194.
Merged images (RPA194, red; DNA, blue) are shown. Scale bar, 10 mm.
See also Figure S2.Degradation of the Largest Pol I Subunit Is Conserved
among Eukaryotes
To test whether the effect of BMH-21 on rRNA synthesis is con-
served among eukaryotes, we exposed exponentially growing
Saccharomyces cerevisiae cells to 50 mM BMH-21 and
measured rRNA synthesis and A190 abundance (the yeast ho-
molog of RPA194). To measure rRNA synthesis, we measured
the abundance of pre-rRNA segments ITS1 or 50ETS. These
pre-rRNA segments are rapidly processed after their synthesis,so intact pre-RNA measured is indicative of newly synthesized
rRNA. We found that BMH-21 caused a robust, rapid inhibition
of rRNA synthesis (Figure 5A) and degradation of A190 (Fig-
ure 5B). These data suggest that the cellular response to
BMH-21 is conserved across eukaryotic species.
Because the effects of BMH-21 are conserved, we took
advantage of the genetic capabilities of the yeast system to
test the model that BMH-21 targets the Pol I transcription elon-
gation complex. Previous studies have identified point mutationsCell Reports 23, 404–414, April 10, 2018 407
Figure 3. BMH-21 Causes RPA135 Cellular Redistribution
(A and C) A375 cells were incubated with BMH-21 (1 mM) for the given times, followed by staining of the fixed cells for RPA135 (A, green) or RPA194 (C, red) and
counterstaining for DNA (blue). Scale bar, 10 mm.
(B and D) Quantitative image analysis of nucleolar RPA135 (B, n = 4 biological replicates) or RPA194 (D, n = 5 biological replicates). Mean and SEM are shown.
(E) Western blotting analysis of RPA194 and RPA135 in cytoplasmic and nucleoplasmic fractions. Loading controls are lamin A/C and a-tubulin.
(F) Quantification of n = 3 biological experiments in (E). Data are represented as mean ± SD; p value, Dunnett’s multiple comparison test. ns, non-significant; *p <
0.05; **p < 0.01.
(G) A375 cells were incubated with BMH-21 (1 mM) and/or MG132 (10 mM) for 3 hr followed by cellular fractionation and western blotting analysis for RPA194 and
RPA135. Loading controls are lamin A/C and GAPDH.
408 Cell Reports 23, 404–414, April 10, 2018
Figure 4. RPA135 Is Requisite for the Stability of RPA194
(A) A375 cells were transfected with control siRNAs or siRNAs targeting RPA135 and incubated for 48 hr, and RPA135 transcript was analyzed by qPCR. Fold
change is shown.
(B) Immunofluorescence staining of cells treated as in (A) for RPA135 (green) and RPA194 (red) and counterstained for DNA (blue). Scale bar, 10 mm.
(C) RPA135 was depleted using siRNAs. Cells were incubated for 72 hr following transfection with the siRNAs and then treated with BMH-21 (1 mM) for 3 hr.
Western blotting for RPA135, RPA194, and UBF and A43 as a loading controls.
(D) Quantification of n = 3 biological experiments in (C). Data are represented as mean ± SD; p, Student’s two-tailed t test. ns, non-significant; *p < 0.05; ***p <
0.001.that impair individual steps in transcription by Pol I. Here, we
used two mutations that were identified for their negative effects
on transcription elongation by Pol I (rpa135-D784G and rpa190-
F1205H; Schneider et al., 2007; Viktorovskaya et al., 2013). We
also used a mutation in the RRN3 gene that selectively impairs
transcription initiation (rrn3-S213P; Claypool et al., 2004). We
exposed these mutant cells, as well as wild-type (WT) controls,
to BMH-21 and measured cell viability, rRNA synthesis, and
A190 abundance. We found that both ‘‘elongation’’ mutants
were hypersensitive to BMH-21, consistent with a role for the
compound during the elongation phase of transcription (Fig-
ure 6A). These mutants also displayed clear inhibition of rRNA
synthesis and degradation of A190, similarly to WT (Figures 6B
and 6C). On the other hand, when transcription initiation by Pol
I is impaired because of the rrn3 mutant allele, we found that
the cells’ viability in response to BMH-21 was comparable with
theWT, rRNA synthesis was inhibited, but A190 was not robustly
degraded. These observations are consistent with data
collected using mammalian cells (Figure 2) and with the modelthat Pol I transcription elongation complexes are the substrate
for Pol I subunit degradation after exposure to BMH-21.
BMH-21 Directly Inhibits Transcription Elongation by
Pol I
These genetic and molecular data suggest that BMH-21 inhibits
transcription elongation by Pol I. To test this model directly, we
used a fully reconstituted transcription elongation assay for Pol
I in the presence and absence of BMH-21. We used a modified
yeast rDNA template in which C-residues in the initially tran-
scribed region have been mutated to G. Thus, we initiated tran-
scription in the absence of BMH-21 or CTP, synchronized elon-
gation complexes downstream of the promoter at the first
encoded C (position +56), and we split the reaction. To half of
the reaction, we added 1 mM BMH-21, and to the other, we
added a vehicle control (DMSO). Finally, we added heparin to
both reactions to serve as a trap and ensure single turnover re-
action conditions. After the addition of CTP, we collected sam-
ples as a function of time. RNA products were resolved onCell Reports 23, 404–414, April 10, 2018 409
Figure 5. BMH-21 Effect on Pol I Is Conserved in Yeast
(A) Cells were grown in YEPD and treated with 50 mM BMH-21 for indicated
times and harvested. RNA was purified and analyzed with RT-qPCR using
primers targeting the pre-rRNA segment ITS1, the abundance of which is
indicative of newly synthesized rRNA, and to ACT1 mRNA, for normalization
purposes. Data shown are representative of n = 3, and error bars represent SD
of technical replicates.
(B) Cells were grown in YEPD and treated with 50 mM BMH-21 for indicated
times. Cells were harvested, lysed, and analyzed for A190 and Pgk1 abun-
dance with western blot analysis. Data shown are averages of n = 3, and error
bars represent SEM of biological replicates. Significance was calculated using
one-way ANOVA. **p < 0.01.polyacrylamide gels and visualized by phosphorimaging. A
representative gel is displayed in Figure 7A and quantification
in Figure 7B. The addition of BMH-21 to the elongation com-
plexes induced the accumulation of shorter products that repre-
sent major pause sites in the template. Consistent with the
appearance of these paused populations, we observed much
slower accumulation of the full-length product. Thus, BMH-21
directly inhibits transcription elongation by Pol I. In addition to
the dramatic effect of BMH-21 on transcription elongation rate,
we observed a modest (20%) decrease in the amount of full-
length product accumulation. This observation suggests that
BMH-21 directly induces either premature termination or irre-
versible arrests of transcription elongation complexes. Together,410 Cell Reports 23, 404–414, April 10, 2018all of these biochemical observations are consistent with the
data collected from cell lines and in yeast strains supporting a
role for BMH-21 in direct inhibition of Pol I transcription
complexes.
DISCUSSION
Our studies show that BMH-21 inhibits rRNA synthesis in cancer
cells rapidly and robustly. The inhibition of rRNA synthesis leads
to proteasome-dependent degradation of the largest subunit of
Pol I, RPA194 (Peltonen et al., 2014a). The rapid degradation
of RPA194 closely correlated with decreased cancer cell survival
in response to BMH-21. In order to understand the basis of this
previously unknown degradation pathway for Pol I, it was neces-
sary to identify how BMH-21 targets Pol I transcription. We show
here that BMH-21 causes rapid inhibition of Pol I transcription
and decreased occupancy of Pol I on the rDNA. These rapid ki-
netic effects are observed before the abundance of RPA194 is
robustly decreased. Thus, transcriptionally active Pol I is some-
how perturbed or evicted from the rDNA prior to RPA194 degra-
dation. Remarkably, this effect of the compound is conserved in
yeast, and mutations that impair transcription elongation by Pol I
result in hypersensitivity to BMH-21. Taken together with the fact
that Pol I transcription elongation is directly inhibited by BMH-21
in vitro, we conclude that BMH-21 can have a direct effect on
rRNA synthesis and propose that it activates a conserved
pathway that monitors the efficiency of Pol I transcription. Here
we use the term ‘‘checkpoint’’ to describe the surveillance of
the integrity Pol I transcription. Activation of this ‘‘checkpoint’’
by BMH-21 or potentially other naturally occurring stresses spe-
cifically leads to the degradation of the largest subunit of Pol I.
Polymerases frequently encounter lesions or blocks in their
templates. In response to unsuccessful resolution of Pol II blocks
at DNA lesions, the Pol II subunit Rpb1 is marked for protea-
some-mediated degradation (Wilson et al., 2013). The degrada-
tion of Rpb1 leads to removal of the Pol II complex fromDNA and
is considered necessary for cell survival. Our work has identified
a similar clearance mechanism for Pol I. We have shown that
stimuli that cause destabilization of the large subunits of Pol I
and Pol II are different. BMH-21 does not cause degradation of
Pol II Rpb1, and conversely, UV that causes Rpb1 destabilization
has no effect on RPA194 degradation either in mammalian cells
(Peltonen et al., 2014a) or in the yeast (Richardson et al., 2012).
The degradation of RPA194 is mediated through the protea-
some, and a RPA194 deubiquitinating enzyme has been identi-
fied in the mammals (USP36; Peltonen et al., 2014a) and its
counterpart Upb10 in yeast (Richardson et al., 2012). In yeast,
A190 is particularly prone for degradation at low temperatures
when upb10 is deleted, suggesting activation of the checkpoint
also by physiological signals. In order to resolve these transcrip-
tion blocks, the enzyme is disengaged from rDNA, and RPA194/
A190 is marked for degradation. Because the rDNA is one of the
most highly transcribed loci in growing cells, BMH-21 is more
likely to intercalate into these loci and selectively perturb rDNA
transcription. The observed degradation of RPA194 only in the
cancer cells, but not in normal cells, further supports this model
and identifies the rDNA as a clear vulnerability rapidly prolifer-
ating cells.
Figure 6. BMH-21 Exposure Results in De-
fects in Pol I Elongation, and Inhibiting Initi-
ation Rescues A190 Degradation
(A) Cultures were grown in YEPD liquid media and
harvested. For the spot assay, 10-fold dilutions
were made, the first being 0.1 at A600, and 5 mL
were plated on YEPD plates containing indicated
concentrations of BMH-21. Plates were incubated
at indicated temperatures for 3 days.
(B) Cells were grown in YEPD and treated with
50 mM BMH-21 for 60 min. Cells were harvested,
lysed, and analyzed for A190 and Pgk1 abundance
with western blot analysis. Data shown are aver-
ages of n R 3, and error bars represent SEM of
biological replicates. Significance was calculated
using one-way ANOVA. *p < 0.05; **p < 0.01.
(C) Cells were grown in YEPD and treated with
50 mMBMH-21 for 30min and harvested. RNAwas
purified and analyzed for 50ETS abundance with
RT-qPCR. Data shown are representative of n = 3,
and error bars represent SD of technical replicates.The change in RPA194 half-life by BMH-21 is profound,
whereas other Pol I subunits, with the exception of a minor
decrease in RPA135, are not affected (Peltonen et al., 2014a).
However, the nucleolar abundance of RPA135 decreases and
it is relocated in the cytoplasm after treatment with BMH-21.
We assessed whether RPA135 affects RPA194 stability.
Remarkably, the depletion of RPA135 substantially decreased
the abundance of RPA194. Furthermore, BMH-21-mediated
degradation of RPA194 was abrogated in cells with RPA135
knockdown. These findings suggest that RPA135 is required
for the stability of RPA194 and are concordant with our previous
demonstration in yeast that A190 and A135 maintain a stable as-
sociation through multiple rounds of transcription (Schneider
and Nomura 2004). The implication is profound, suggesting
that one subunit directly governs the stability of the catalytic
core of the enzyme.
The primary pathways regulating ribosome biogenesis are
conserved between yeast and mammals. Here, we find a
remarkable conservation of the key characteristics of the Pol I in-
hibitor that includes inhibition of rRNA synthesis, decreased
abundance of A190 and loss of yeast fitness. This enabled us
to use previously characterized Pol I elongation mutant strains
of A190 and A135 that have compromised elongation rates yetCmaintain viability (Schneider et al., 2007;
Viktorovskaya et al., 2013). Both mutants,
compared with WT and an initiation-
impaired rrn3 mutant strain, displayed
increased sensitivity to BMH-21, empha-
sizing that the Pol I inhibitor particularly
hindered the growth of elongation
defective cells. Furthermore, BMH-21
decreased the abundance of A190 in the
elongation-impaired mutants, but not
in the initiation-impaired mutant strain,
which was concordant with the regulation
of RPA194 turnover observed in the
cancer cells. These studies support andpromote the concept that the elongation phase of transcription
presents a previously unappreciated vulnerability that can be
targeted for therapeutic intervention.
There are technical and conceptual limitations of the data and
interpretation. For example, Pol I inhibition by BMH-21 may only
affect loading of the polymerase at the promoter, or BMH-21
may inhibit promoter escape. Both scenarios would be consistent
with the rapid kinetics of inhibition and reduced Pol I rDNA asso-
ciation. However, it would be more difficult to explain how Pol I
degradation is induced when these steps are inhibited. We
showed that genetic depletion of members of the preinitiation
complex does not activate RPA194/A190 degradation, but in
contrast, the preinitiation complex is needed for polymerase
decay. Hence, polymerase loading is required. These findings
do not rule out that BMH-21 blocks promoter escape and need
to be addressed in future studies. We note, however, that we
do not observe increased Pol I pausing at the promoter on the ba-
sis of ChIP. However, ChIP may have technical limitations due to
changes in the antigen or accessibility to chromatin, or lack sensi-
tivity because of rapid clearance in detection of paused com-
plexes. Both the in vitro and genetic data are consistent with inhi-
bition of elongation activating the depletion of RPA194. However,
it also plausible that additional points of intervention exist.ell Reports 23, 404–414, April 10, 2018 411
Figure 7. BMH-21 Directly Inhibits Pol I Transcription Elongation
(A) Promoter-dependent transcription was performed using purified yeast Pol I
and required transcription initiation factors in vitro. Transcription was initiated
by addition of 200 mM ATP and GTP and 20 mM UTP (+a32P-UTP), resulting in
elongation to the first encoded C residue (at +56). The reaction was split
equally, and BMH-21 (1 mM) or an equal volume of DMSO was added to the
separate reactions, followed by addition of CTP (200 mM), and samples were
collected as a function of time. RNAwas purified and run on an 8% acrylamide
denaturing gel. The gel was dried, exposed to a phosphor-image screen, and
visualized. Positions of relevant RNA products are labeled.
(B) Amount of 32P-RNA detected in the full-length product was quantified and
plotted as a function of time.The kinetics of the induction of this checkpoint presents
another fascinating but complicated question. Transcription of
the rDNA is almost fully inhibited within 30 min, and at the
same time both RPA194 and RPA135 undergo changes in their
localization. The cytoplasmic translocation of RPA135 is pre-
vented by proteasome inhibition, which is indicative that
RPA135 localization depends on stability of RPA194. RPA194
half-life is decreased from more than 20 hr to 1 hr (Peltonen
et al., 2014a) and is thus lagging behind transcription inhibition.
It is possible that this kinetic delay represents a surplus of
RPA194/RPA135 complexes and/or that only complexes physi-
cally associating with rDNA are targeted for degradation. Inhibi-
tion of transcription initiation protects RPA194 from decay but
does not rescue rRNA synthesis. Thus, this checkpoint monitors412 Cell Reports 23, 404–414, April 10, 2018actively transcribing Pol I complexes. These complexes are
somehow marked for degradation and cleared from the DNA.
What is the initial mark on the enzyme? Is it ubiquitin? What ac-
tivates the mark, and are there several marking events as for Pol
II? Does the marking require the formation and relocalization of
RPA194 to the nucleolar caps observed preceding the degrada-
tion? What factors govern this checkpoint? These and other
questions must be answered to reveal the mechanism by which
eukaryotes monitor and protect the metabolism of the rDNA.
Several chemical tools have recently been described that
interfere with Pol I transcription. CX-5461 and ellipticine stabilize
G-quadruplex structures and cause DNA damage (Andrews
et al., 2013; Brown et al., 2011; Xu et al., 2017). Ellipticine targets
the preinitiation complex at the rDNA promoter, and similarly,
CX-5461 has been suggested to inhibit the preinitiation complex
engagement with the rDNA promoter (Andrews et al., 2013; Dry-
gin et al., 2011). Importantly, several chemotherapeutic agents,
such as topoisomerase I and II poisons, inhibit Pol I transcription
by blocking rDNA unwinding (Burger et al., 2010). RPA194 abun-
dance or Pol I activity could be potentially useful biomarkers for
identification of cancers sensitive to Pol I inhibitor therapies. To
facilitate the latter, we have recently developed an RNAprobe for
the detection of rRNA transcription in paraffin-embedded tumor
samples. This probe, detecting the short-lived 50ETS precursor
rRNA, directly reveals the remarkable increase in Pol I activity
between benign and carcinoma lesions (Guner et al., 2017).
These findings provide impetus for the translation of Pol I inhib-
itory strategies. Detailed understanding of the mechanisms of
action of each drug will be essential for the success of this goal.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
A375 melanoma (CRL-1619) and U-2 OS osteosarcoma (HTB-96) cells were
from American Type Culture Collection. These cell lines were authenticated
using STR analysis by Johns Hopkins Genetic Resources Core Facility and
tested periodically forMycoplasma using qPCRwith negative results. The cells
weremaintained at 37C in a humidified atmosphere containing 5%CO2. A375
cells were cultured in DMEM supplementedwith 10% fetal bovine serum (FBS)
and 4.5 g/L glucose and U-2 OS cells in DMEM with 15% FBS. The reagent
used in this study was 12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide,
N-[2(dimethylamino)ethyl]-12-oxo (BMH-21), which was synthesized as
described by Colis et al. (2014b) and verified for purity using liquid chromatog-
raphy/mass spectrometry (LC/MS) and 1H nuclear magnetic resonance
(NMR). MG132 was from Sigma-Aldrich and from Enzo LifeSciences.
Viability Assays
Cell viability was determined using WST-1 cell proliferation reagent (Roche Di-
agnostics), CellTiter Blue cell viability assay (Promega), or by counting the cells
using Cellometer Auto T4 (Nexelcom Bioscience LLC).
RNAi
For RNAi using small interfering siRNAs, cells were transfected with 10 nM of
targeting gene or negative control siRNAs using Lipofectamine RNAiMAX
(Invitrogen), and the cells were incubated for 48–72 hr. The following siRNAs
were used: UBTF (115986 and 108497), RRN3 (s29324 and s29325), TAF1C
(s17171 and s17172), and POLR1B/RPA135 (s38603 and s38605) (Ambion,
Thermo Fisher Scientific).
Immunofluorescence and Image Analysis
For all immunofluorescence procedures, we followed our earlier protocols
(Peltonen et al., 2014a). Cells grown on coverslips were fixed in 3.5%
paraformaldehyde or 100% methanol, permeabilized with 0.5% NP-40 lysis
buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.5% NP-40, and 50 mM
NaF), and blocked in 3% BSA. The following primary antibodies were used:
POLR1B/RPA135 (4H6; Santa Cruz Biotechnology), POLR1A/RPA194 (C-1;
Santa Cruz Biotechnology), NPM (FC-61991; Invitrogen), NCL (4E2; Abcam),
and fibrillarin (ab5821; Abcam). Secondary antibodies used were Alexa 488
and Alexa 594-conjugated anti-mouse and anti-rabbit antibodies (Invitrogen).
DNA was stained with Hoechst 33342. Images were captured using DM6000B
wide-field fluorescence microscope (Leica). The microscope was equipped
with a Hamamatsu Orca-Flash 4.0 V2 sCMOS camera and LAS X software
by using 403/1.25–0.75 HCX PL APO CS oil and 633/1.40–0.60 HCX PL
APO Lbd.bl. oil objectives. Quantitative image analysis of nucleolar protein
expression was as described in Peltonen et al. (2014a) and was conducted
on at least 200 cells per sample on three to five fields.
Subcellular Fractionation
Cytoplasmic and nucleoplasmic fractions were prepared in the following
steps. Cells were lysed with hypotonic buffer (10 mM HEPES [pH 7.9],
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and protease inhibitors), and
50 mg/mL digitonin was added. Cells were centrifuged at 2,000 3 g for 6 min
to isolate cytoplasmic fraction, and the cell pellet containing nuclei was subse-
quently lysed with isotonic buffer (5 mM HEPES [pH 8.0], 1.5 mM MgCl2,
10 mM KCl, 0.5 mM DTT, 330 mM sucrose, and protease inhibitors) and
layered over sucrose buffer (880 mM sucrose, 0.5 mM MgCl2, and protease
inhibitors). The nuclear fraction was centrifuged at 13,200 rpm for 30 min.
Nuclei were then lysed with nucleoplasmic extraction buffer (20 mM HEPES
[pH 7.9], 1.5 mM MgCl2, 150 mM KCl, 0.5 mM DTT, 0.2 mM EDTA, 10% glyc-
erol, and protease inhibitors), sonicated, and centrifuged. After centrifuging at
15,000 3 g for 20 min, the supernatant was recovered.
Immunoblotting
Cells were lysed in RIPA lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl,
1%NP-40, 0.1%SDS, and 1% sodium deoxycholate) supplemented with pro-
tease inhibitors (Roche), sonicated, and centrifuged at 13,200 rpm for 15 min.
Protein concentrations were measured using the Dc-Protein Kit (Bio-Rad).
Equal amounts of protein were separated on SDS-PAGE, blotted, probed for
target proteins, and detected using ECL (Perkin Elmer). The primary antibodies
used for detection were UBF (F-9; Santa Cruz Biotechnology), RRN3
(ab112052; Abcam), TAF1C (ab134394; Abcam), POLR1A/RPA194 (C-1;
Santa Cruz Biotechnology), POLR1B/RPA135 (H-15; Santa Cruz Biotech-
nology), RPA43 (HPA022416; Sigma-Aldrich), a-tubulin (10D8; Santa Cruz
Biotechnology), lamin A/C (H-110; Santa Cruz Biotechnology), and GAPDH
(14C10; Cell Signaling Technology). Horseradish peroxidase (HRP)-conju-
gated secondary antibodies were from DAKO or Santa Cruz Biotechnology.
Protein densitometry analysis was conducted using ImageJ software, and
the mean value normalized with loading control was used as final protein
band quantification.
qPCR and ChIP
qPCR for the mammalian cells was conducted essentially as described in
Peltonen et al. (2014a). The following primers were used: POLR1B (forward
GCCCAGCGGGCCTAGCCTAA, reverse TGATATCAGCCTGCACCGCGA),
50ETS (forward +21 CGACCTGTCGTCGGAGAG, reverse +82 GGTCACCGT
GAGGCCAGA; forward +1902 ATGGACGAGAATCACGAGCG, reverse +1952
CAGCCACGAACCCGACAC; forward +3288 GAAGCGTCGCGGGTCT, re-
verse +3433 CACGCGACACGACCAC). Isolation of chromatin, immunopre-
cipitation, and qPCR to detect rDNA sequences was as described in Peltonen
et al. (2014a).
Yeast Strains and Spot Assay
The following yeast strains were used: DAS217: MAT a ade2-1 ura3-1 trp1-1
leu2-3,112 his3-11,15 can1-100; DAS1064: same as DAS217, but rpa190-
F1205H; DAS178: same as DAS217, but MAT a and rpa135-D784G;
DAS659: same as DAS217, but MAT a and rrn3-S213P; DAS937: same as
DAS217, but A190-3HA7his::LEU2; DAS1061: same as DAS1064, but A190-
3HA7his::URA3; DAS1062: same as DAS178, but A190-3HA7his::URA3; and
DAS1063: same as DAS659, but A190-3HA7his::URA3. For the spot assay,the cultures were grown in YEPD liquid media and harvested. For the
spot assay, 10-fold dilutions were made, the first being 0.1 A600, and 5 mL
per dilution was plated on YEPD plates containing indicated concentrations
of BMH-21. Plates were incubated at 30C for 3 days.
Preparation of Yeast Lysates and Western Analysis
Cells were grown in YEPD and, in early log phase, were treated with 50 mM
BMH-21 in 0.1 M NaH2PO4 or an equivalent volume of the vehicle. Ten milliliters
of culture was harvested via centrifugation and washed with cold RIPA buffer.
Cells were lysed using a FastPrep homogenizer. Samples were loaded onto
8% polyacramide gels, transferred to polyvinylidene difluoride (PVDF) mem-
branes, and probed with antibodies (a-HA 12CA5 from Sigma-Aldrich to visu-
alize A190 and a-Pgk1 22C5D8 from Thermo Fisher Scientific to visualize
PGK1). A secondary a-mouse IgG conjugated to HRP (A9044; Sigma-Aldrich)
was used for detection. Western blots were visualized with chemiluminescence
(Chemidoc; Bio-Rad), and analyzed using Image Lab software.
Yeast RNA Isolation and RT-qPCR
Cells were grown in YEPD and, in early log phase, were treated with 50 mM
BMH-21 in 0.1MNaH2PO4 or an equivalent volume of the vehicle. Onemilliliter
of culture was flash-frozen in a dry ice/ethanol bath. Cells were lysed using hot
phenol lysis, and RNA was purified with acidic phenol/chloroform extraction
followed by precipitation in 1 M ammonium acetate in ethanol. cDNA was
synthesized using the SuperScript First-Strand Synthesis system (Thermo
Fisher Scientific). qPCR was performed using probes for ITS1, 50ETS, ACT1,
and 18S rRNA using the ViiA 7 Real Time PCR system (Thermo Fisher
Scientific), and data were analyzed using QuantStudio Real-Time PCR Soft-
ware. The following primers were used: ITS1 forward 50-TGGGCAAGAAGA
CAAGAGATGGAG-30; reverse 50-GTTTGTGTTTGTTACCTCTGGGCC-30; 50-
ETS forward 50-AATAGCCGGTCGCAAGACT-30; reverse 50-TCACGGAATGG
TACGTTTGA-30; ACT1 forward 50-TCCGGTGATGGTGTTACTCA-30; reverse
50-GGCCAAATCGATTCTCAAAA-30; 18S forward 50-TGGCCTACCATGGTTT
CAA-30; reverse 50-CTTGGATGTGGTAGCCGTTT-30.
In Vitro Transcription
Assays for transcription elongation by Pol I were performed as described pre-
viously (Viktorovskaya et al., 2013) with the notable exception that BMH-21
was added to a final concentration of 1 mM to the synchronized elongation
complexes (after initiation of transcription but prior to CTP release). An equal
volume of vehicle (DMSO) was added to control samples.
Statistical Methods
The following statistical methods were used: Student’s two-tailed t test, Dun-
nett’s multiple-comparison test, and one-way ANOVA; p values less than 0.05
were considered significant. The method used is indicated in each figure
legend.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and can be found with this
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